# Board of Supervisors Minutes: November 2, 2021 - Meeting date: 2021-11-02 - Document type: minutes - Source format: PDF - Extracted pages: 24 - [Canonical HTML transcript](https://sfbos.info/documents/802/2021-11-02-minutes) - [Authoritative City source](https://sfgov.legistar.com/View.ashx?M=M&ID=901937&GUID=519C8905-694E-4D68-8B48-3FD95D9C0792) > This text was extracted for search and accessibility. The linked City source is the authoritative public record. ## Structured legislative records ### File 210710: Approving Conditional Use Authorization - 575 Vermont Street - Pages: 11-12 - Vote 1: approval, likely final - Action: 210710 [Approving Conditional Use Authorization - 575 Vermont Street] Motion approving the decision of the Planning Commission by its Motion No. 20921, approving a Conditional Use Authorization, identified as Planning Case No. 2020-000886CUA, for a proposed project located at 575 Vermont Street; and making environmental findings, and findings of consistency with the General Plan, and the eight priority policies of Planning Code, Section 101.1. (Clerk of the Board) Motion No. M21-152 Supervisor Walton, seconded by Supervisor Ronen, moved that this Motion be APPROVED. The motion carried by the following vote: - Ayes: Chan, Haney, Mandelman, Mar, Melgar, Peskin, Preston, Ronen, Stefani, Walton - Absent: Safai ### File 210711: Conditionally Disapproving Conditional Use Authorization - 575 Vermont Street - Pages: 12 - Vote 1: tabling - Action: 210711 [Conditionally Disapproving Conditional Use Authorization - 575 Vermont Street] Motion conditionally disapproving the decision of the Planning Commission by its Motion No. 20921, approving a Conditional Use Authorization, identified as Planning Case No. 2020-000886CUA, for a proposed project at 575 Vermont Street, subject to the adoption of written findings by the Board in support of this determination. (Clerk of the Board) (Charter, Section 4.105, and Planning Code, Section 308.1(d), provides that the Board of Supervisors may disapprove the decision of the Planning Commission by a vote of not less than two-thirds (8 votes) of the members of the Board.) Supervisor Walton, seconded by Supervisor Ronen, moved that this Motion be TABLED. The motion carried by the following vote: - Ayes: Chan, Haney, Mandelman, Mar, Melgar, Peskin, Preston, Ronen, Stefani, Walton - Absent: Safai ### File 210712: Preparation of Findings Related to Conditional Use Authorization - 575 Vermont Street - Pages: 12-13 - Vote 1: tabling - Action: 210712 [Preparation of Findings Related to Conditional Use Authorization - 575 Vermont Street] Motion directing the Clerk of the Board to prepare findings in support of the Board of Supervisors' disapproval of the proposed Conditional Use Authorization, identified as Planning Case No. 2020-000886CUA, for a proposed project at 575 Vermont Street. (Clerk of the Board) Supervisor Walton, seconded by Supervisor Ronen, moved that this Motion be TABLED. The motion carried by the following vote: - Ayes: Chan, Haney, Mandelman, Mar, Melgar, Peskin, Preston, Ronen, Stefani, Walton - Absent: Safai ### File 211113: Hearing - Committee of the Whole - Existing Litigation - AmerisourceBergen Corp., Cardinal Health, Inc., and McKesson Corp. - City to Receive up to $50 Million (File 211071) - Johnson & Johnson - City to Receive up to $11 Million (File 211072) - Pages: 13-14 ## Extracted text ### [Page 12](https://sfbos.info/documents/802/2021-11-02-minutes#page-12) Board of Supervisors Meeting Minutes 11/2/2021 210711 [Conditionally Disapproving Conditional Use Authorization - 575 Vermont Street] Motion conditionally disapproving the decision of the Planning Commission by its Motion No. 20921, approving a Conditional Use Authorization, identified as Planning Case No. 2020-000886CUA, for a proposed project at 575 Vermont Street, subject to the adoption of written findings by the Board in support of this determination. (Clerk of the Board) (Charter, Section 4.105, and Planning Code, Section 308.1(d), provides that the Board of Supervisors may disapprove the decision of the Planning Commission by a vote of not less than two-thirds (8 votes) of the members of the Board.) Supervisor Walton, seconded by Supervisor Ronen, moved that this Motion be TABLED. The motion carried by the following vote: Ayes: 10 - Chan, Haney, Mandelman, Mar, Melgar, Peskin, Preston, Ronen, Stefani, Walton Absent: 1 - Safai 210712 [Preparation of Findings Related to Conditional Use Authorization - 575 Vermont Street] Motion directing the Clerk of the Board to prepare findings in support of the Board of Supervisors' disapproval of the proposed Conditional Use Authorization, identified as Planning Case No. 2020-000886CUA, for a proposed project at 575 Vermont Street. (Clerk of the Board) Supervisor Walton, seconded by Supervisor Ronen, moved that this Motion be TABLED. The motion carried by the following vote: Ayes: 10 - Chan, Haney, Mandelman, Mar, Melgar, Peskin, Preston, Ronen, Stefani, Walton Absent: 1 - Safai Supervisor Safai was noted present at 3:17 p.m. City and County of San Francisco Page 883 Printed at 2:46 pm on 12/3/21 ### [Page 13](https://sfbos.info/documents/802/2021-11-02-minutes#page-13) Board of Supervisors Meeting Minutes 11/2/2021 SPECIAL ORDER 3:00 P.M. President Walton requested File Nos. 211113, 211115, 211071, and 211072 be called together. Board of Supervisors Sitting as a Committee of the Whole 211113 [Hearing - Committee of the Whole - Existing Litigation - AmerisourceBergen Corp., Cardinal Health, Inc., and McKesson Corp. - City to Receive up to $50 Million (File 211071) - Johnson & Johnson - City to Receive up to $11 Million (File 211072)] Hearing of the Board of Supervisors sitting as a Committee of the Whole on November 2, 2021, at 3:00 p.m., to hold a public hearing to consider the proposed Ordinances (File Nos. 211071 and 211072) regarding existing litigation relating to the partial settlement of the lawsuit filed on behalf of the City and County of San Francisco and the People of the State of California against three large distributors of prescription opioids (AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation) for abatement funds in the range of $27 million to $50 million to be paid over 18 years, entitled The City and County of San Francisco and the People of the State of California v. Purdue Pharma L.P., Richard S. Sackler, Jonathan D. Sackler, Mortimer D.A. Sackler, Kathe A. Sackler, Ilene Sackler Lefcourt, Beverly Sackler, Theresa Sackler, David A. Sackler, Trust for the Benefit of Members of the Raymond Sackler Family, Rhodes Pharmaceuticals L.P., Cephalon, Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., Endo International Plc, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Insys Therapeutics, Inc., Mallinckrodt Plc, Mallinckrodt LLC, Allergan Plc F/K/A Actavis Plc, Watson Pharmaceuticals, Inc. N/K/A Actavis, Inc., Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc. F/K/A/ Watson Pharma, Inc., AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation; and the partial settlement of the lawsuit filed on behalf of the City and County of San Francisco and the People of the State of California against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc., for abatement funds in the range of $6 million to $11 million to be paid over nine years, entitled The City and County of San Francisco and the People of the State of California v. Purdue Pharma L.P., Richard S. Sackler, Jonathan D. Sackler, Mortimer D.A. Sackler, Kathe A. Sackler, Ilene Sackler Lefcourt, Beverly Sackler, Theresa Sackler, David A. Sackler, Trust for the Benefit of Members of the Raymond Sackler Family, Rhodes Pharmaceuticals L.P., Cephalon, Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., Endo International Plc, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Insys Therapeutics, Inc., Mallinckrodt Plc, Mallinckrodt LLC, Allergan Plc F/K/A Actavis Plc, Watson Pharmaceuticals, Inc. N/K/A Actavis, Inc., Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc. F/K/A/ Watson Pharma, Inc., AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation; scheduled pursuant to Motion Nos. M21-148 (File No. 211112) and M21-149 (File No. 211114), approved on October 26, 2021. (Clerk of the Board) President Walton opened the public hearing and Supervisor Preston provided introductory remarks. The President then inquired as to whether any individual wished to address the Board regarding the Hearing to consider existing litigation. Anne Pearson (Office of the City Attorney); presented an overview of the hearing matter and responded to questions raised throughout the discussion. Speaker; spoke on various concerns related to the hearing matter. There were no other speakers. President Walton closed public comment, declared the matter heard and filed, adjourned as a Committee of the Whole, and reconvened as the Board of Supervisors. HEARD AND FILED Committee of the Whole Adjourn and Report City and County of San Francisco Page 884 Printed at 2:46 pm on 12/3/21